We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-18.65%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$626M
AUM Growth
-$126M
Cap. Flow
+$63M
Cap. Flow %
10.07%
Top 10 Hldgs %
43.21%
Holding
89
New
9
Increased
11
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
OMER icon
Omeros
OMER
+$24.5M
2
SAGE
Sage Therapeutics
SAGE
+$14.8M
3
RMTI icon
Rockwell Medical
RMTI
+$10.1M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$8.75M
5
HRTX icon
Heron Therapeutics
HRTX
+$8.19M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$41.8M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$8.24M
3
NGNE icon
Neurogene
NGNE
+$1.5M
4
FOLD
Amicus Therapeutics
FOLD
+$784K
5
NSTG
NanoString Technologies, Inc.
NSTG
+$627K

Sector Composition

Rank Sector Weight
1 Healthcare 80.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNVC
51
DELISTED
GenVec, Inc.
GNVC
$2.72M 0.43%
117,624
– –
TLPH icon
52
Talphera
TLPH
$70.6M
$2.59M 0.41%
42,500
– –
CBIO
53
Crescent Biopharma
CBIO
$608M
$2.57M 0.41%
4,590
– –
IMDZ
54
DELISTED
Immune Design Corp.
IMDZ
$2.31M 0.37%
189,000
– –
TPST icon
55
Tempest Therapeutics
TPST
$14.2M
$2.14M 0.34%
86
– –
BPMC
56
DELISTED
Blueprint Medicines
BPMC
$2.13M 0.34%
100,000
– –
NGNE icon
57
Neurogene
NGNE
$686M
$2.11M 0.34%
7,500
-6,495
-46% -$1.5M
FOLD
58
DELISTED
Amicus Therapeutics
FOLD
$2.1M 0.34%
150,000
-50,000
-25% -$784K
SGMO
59
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.04M 0.33%
361,000
– –
DARE icon
60
Dare Bioscience
DARE
$20.1M
$2.02M 0.32%
4,595
– –
DRNA
61
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.01M 0.32%
245,000
– –
ARAV
62
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.96M 0.31%
28,333
– –
AVEO
63
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.92M 0.31%
158,772
– –
KIN
64
DELISTED
Kindred Biosciences, Inc.
KIN
$1.71M 0.27%
328,497
– –
HTGM
65
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$1.53M 0.24%
1,117
– –
PVCT
66
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$1.26M 0.2%
2,200,000
– –
AGRX
67
DELISTED
Agile Therapeutics
AGRX
$1.23M 0.2%
91
– –
SRRA
68
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.09M 0.17%
+1,329
New +$1.5M
ASND icon
69
Ascendis Pharma A/S
ASND
$16B
$1.09M 0.17%
61,500
– –
NEOS
70
DELISTED
Neos Therapeutics, Inc
NEOS
$1.05M 0.17%
+50,000
New +$1.1M
CLRB icon
71
Cellectar Biosciences
CLRB
$20.5M
$1.04M 0.17%
18
– –
CFRX
72
DELISTED
ContraFect Corporation
CFRX
$1.04M 0.17%
293
– –
AKBA icon
73
Akebia Therapeutics
AKBA
$354M
$969K 0.15%
100,300
– –
SCYX icon
74
SCYNEXIS
SCYX
$53.6M
$723K 0.12%
1,242
– –
AKTX
75
Akari Therapeutics
AKTX
$13.6M
$687K 0.11%
36
– –
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2015 Portfolio in Review

As of Q3 2015, Cormorant Asset Management held 89 positions worth $626M, down 17% from $752M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Cormorant Asset Management deployed $63M of net new capital in Q3 2015, opening 9 new positions and adding to 11 existing holdings. Its largest new stake was Sage Therapeutics: 240,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier.

On the sell side, the largest reduction was Neurogene, an estimated $1.5M trimmed.

  • Cormorant Asset Management's largest Q3 2015 buy was Sage Therapeutics: 240,000 shares worth $10.2M.
  • Cormorant Asset Management added most to Omeros in Q3 2015, an estimated $24.5M increase.
  • Cormorant Asset Management's biggest Q3 2015 reduction was Neurogene, cutting an estimated $1.5M.
  • Cormorant Asset Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $41.8M.
  • Cormorant Asset Management's ten largest holdings make up 43% of its $626M portfolio in Q3 2015.
  • Cormorant Asset Management opened 9 new positions and closed 2 in Q3 2015.
  • Cormorant Asset Management's portfolio value fell 17% quarter-over-quarter to $626M.

Based on Cormorant Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.